Trial Profile
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2023 Planned End Date changed from 17 Jul 2023 to 17 Jul 2024.
- 18 Jul 2023 Planned primary completion date changed from 17 Jul 2023 to 17 Jul 2024.